Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker

about

Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale.Survival of Patients with Serous Uterine Carcinoma Undergoing Sentinel Lymph Node Mapping.Time to publication of oncology trials and why some trials are never published.

P2860

Q38932579-25C745E5-1B59-4789-95FB-CC1A91702854 Q40309076-D99499B8-944F-42EC-9C7D-B9CAA24C5654 Q41886616-5904EA32-7175-4A22-85FB-37D1EA2B3204

P2860

Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker

Item

http://www.wikidata.org/entity/Q36868328

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker

@en

type

Item

label

Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker

@en

prefLabel

Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker

@en

P1476

Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker

@en

P2093

Alexia Iasonos

http://www.w3.org/2001/XMLSchema#string

Jaya M Satagopan

http://www.w3.org/2001/XMLSchema#string

Paul B Chapman

http://www.w3.org/2001/XMLSchema#string

P2860

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.

The meaning of interaction

Personalized estimates of breast cancer risk in clinical practice and public health.

Risk factor modification and projections of absolute breast cancer risk

Helping patients decide: ten steps to better risk communication.

P304

2114-2120

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1158/1078-0432.CCR-15-2517

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27141007

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

4856220

http://www.w3.org/2001/XMLSchema#string

Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker

about

P2860

P2860

Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932